 | Up a level |
2020
Al-Batran, S-E., Hofheinz, R. D., Schmalenberg, H., Strumberg, D., Goekkurt, E., Angermeier, S., Zander, T., Potenberg, J., Kopp, H-G., Pink, D., Siegler, G. M., Schenk, M., De Vita, F., Maiello, E., Gaiser, T., Sookthai, D., Bankstahl, U. S., Pauligk, C., Goetze, T. O. and Homann, N. (2020). Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma- Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM. Ann. Oncol., 31. S. S901 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2017
Goetze, T. O., Al-Batran, S-E., Zander, T., Reichart, A., Lindig, U., Kleiss, M., Mueller, L., Bolling, C., Seufferlein, T., Reichardt, P., Kullmann, F., Eschenburg, H., Schmittel, A., Egger, M., Block, A., Pauligk, C. and Schmalenberg, H. (2017). A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041